Skip to main content
. 2021 Feb 1;12:631407. doi: 10.3389/fneur.2021.631407

Table 3.

Comparison between VCI-SVD patients with pathogenic NOTCH3 variants with VCI-SVD patients without pathogenic variants.

NOTCH3 (N = 17) Negative (N = 18) P-value
Male (%) 7 (41.2) 8 (44.4) 1.000
Chinese (%) 16 (94.1) 15 (83.3) 0.603
Mean age at onset (range), years 54.0 (40–64) 55.9 (41–65) 0.344
First symptom: Cognitive impairment (%) 6 (35.3) 11 (61.1) 0.272
First symptom: Parkinsonism (%) 3 (17.6) 2 (11.1) 0.775
Migraine with aura (%) 1 (5.9) 3 (16.7) 0.603
Hemorrhagic stroke (%) 4 (23.5) 1 (5.6) 0.177
Ischemic stroke (%) 8 (47.1) 6 (33.3) 0.500
Mean MMSE (range) 25 (15–30) 22 (0–30) 0.273
Mean MOCA (range) 22 (9–28) 19 (0–29) 0.679
Depression (%) 7 (41.2) 4 (22.2) 0.237
Epilepsy (%) 1 (5.9) 1 (5.6) 1.000
Parkinsonism (%) 6 (35.3) 2 (11.1) 0.121
Tremor (%) 0 (0) 0 (11.1) 1.000
Rigidity (%) 6 (35.3) 2 (11.1) 0.121
Bradykinesia (%) 6 (35.3) 2 (11.1) 0.121
Gait difficulty (%) 4 (23.5) 2 (11.1) 0.506
Hypertension (%) 9 (52.9) 15 (83.3) 0.075
Hyperlipidaemia (%) 9 (52.9) 11 (61.1) 0.738
Diabetes mellitus (%) 1 (5.9) 6 (33.3) 0.088
Smoking (%) 1 (5.9) 2 (11.1) 1.000
Alcohol (%) 0 (0) 1 (5.6) 1.000
Family History (%) 10 (58.8) 6 (33.3) 0.181
MRI
Mean Fazekas score WMH (range) 3 (1–3) 2.5 (1–3) 0.112
Mean Fazekas score PVH (range) 3 (1–3) 2 (0–3) 0.058
Anterior temporal (%) 6 (35.3) 0 (0) 0.008
External capsule (%) 13 (76.5) 9 (50.0) 0.164
PVH (%) 17 (100.0) 16 (88.9) 0.486
WMH (%) 17 (100.0) 18 (100.0) 1.000
BG hyperintensity (%) 16 (94.1) 11 (61.1) 0.041
Infratentorial hyperintensity (%) 11 (64.7) 9 (50.0) 0.500
Microbleeds overall (%) 10 (58.8) 6 (33.3) 0.181
Microbleeds cortical-subcortical (%) 8 (47.1) 5 (27.8) 0.305
Microbleeds BG (%) 10 (58.8) 6 (33.3) 0.181
Microbleeds brainstem (%) 9 (52.9) 4 (22.2) 0.086
Microbleeds cerebellum (%) 7 (41.2) 2 (11.1) 0.060

BG, basal ganglia; MMSE, mini mental state examination; MOCA, Montreal cognitive assessment; PVH, periventricular hyperintensity; WMH, deep white matter hyperintensity.